Skip to Content

New Drug Approvals Archive - April 2014

April 2014

Evzio (naloxone hydrochloride)

Date of Approval: April 3, 2014
Company: Kaleo Inc.
Treatment for: Opioid Overdose

Evzio (naloxone hydrochloride) is an opioid antagonist hand-held auto-injector indicated for the emergency treatment of known or suspected opioid overdose.

Read more: Evzio (naloxone hydrochloride) FDA Approval History

Tanzeum (albiglutide) Injection

Date of Approval: April 15, 2014
Company: GlaxoSmithKline (GSK) plc
Treatment for: Diabetes Type 2

Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.

Read more: Tanzeum (albiglutide) FDA Approval History

Ragwitek (ragweed pollen allergen extract)

Date of Approval: April 17, 2014
Company: Merck & Co., Inc.
Treatment for: Ragweed Allergies

Ragwitek (short ragweed pollen allergen extract) is a sublingual immunotherapy for the treatment of ragweed allergies.

Read more: Ragwitek (ragweed pollen allergen extract) FDA Approval History

Xulane (ethinyl estradiol and norelgestromin) Transdermal System

Date of Approval: April 16, 2014
Company: Mylan Inc.
Treatment for: Contraception

Xulane (ethinyl estradiol and norelgestromin transermal system) is a generic version of Ortho Evra, a birth control patch used to prevent pregnancy.

Read more: Xulane (ethinyl estradiol and norelgestromin) FDA Approval History

Cyramza (ramucirumab) Injection

Date of Approval: April 21, 2014
Company: Eli Lilly and Company
Treatment for: Stomach Cancer

Cyramza (ramucirumab) is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated for the treatment of advanced gastric cancer and non-small cell lung cancer.

Read more: Cyramza (ramucirumab) FDA Approval History

Sylvant (siltuximab) for Injection

Date of Approval: April 22, 2014
Company: Janssen Research & Development, LLC
Treatment for: Multicentric Castleman's Disease

Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease.

Read more: Sylvant (siltuximab) FDA Approval History

Zykadia (ceritinib) Capsules

Date of Approval: April 29, 2014
Company: Novartis Pharmaceuticals Corporation
Treatment for: Non-Small Cell Lung Cancer

Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.

Read more: Zykadia (ceritinib) FDA Approval History

Purixan (mercaptopurine) Oral Suspension

Date of Approval: April 28, 2014
Company: Nova Laboratories, Ltd.
Treatment for: Acute Lymphoblastic Leukemia

Purixan (mercaptopurine) is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia.

Read more: Purixan (mercaptopurine) FDA Approval History

Incruse Ellipta (umeclidinium) Inhalation Powder

Date of Approval: April 30, 2014
Company: GlaxoSmithKline
Treatment for: Chronic Obstructive Pulmonary Disease -- Maintenance

Incruse Ellipta (umeclidinium) is an anticholinergic bronchodilator indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Read more: Incruse Ellipta (umeclidinium) FDA Approval History

New Drug Approvals Archive